RxDoctor Payments Data

Naina Sinha, MD

Internal Medicine · New York, NYNPI 1144310327

Payments from drug & device makers

$22,444in general payments, 2019–2025

Across 19 payments — averaging $1181.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sanofi US Services Inc.$21K
  • Sanofi-aventis U.S. LLC$388
  • Cequr Corporation$195
  • Novo Nordisk$179
  • Mannkind Corporation$119
  • Abbott$78
  • plus $75 from 3 others

What the payments were for

  • Food & beverage$91689%
  • Gifts$11911%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$22,444 in reported general payments places this provider in the 95th percentile of 9,771 internal medicine providers in New York.

See all internal medicine providers in New York

Medicare billing

Part B allowed, 2024
$205,746
Medicare patients
550
Services billed
2,886

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide159$277,326
MounjaroTirzepatide78$86,227
JardianceEmpagliflozin41$56,565
TradjentaLinagliptin39$44,016
JanuviaSitagliptin Phosphate21$30,023
Tresiba Flextouch U-100Insulin Degludec59$25,273
ProliaDenosumab14$23,451
TrulicityDulaglutide16$15,657
SynthroidLevothyroxine Sodium142$12,575
VascepaIcosapent Ethyl15$11,737
Gvoke Hypopen 2-PackGlucagon16$9,415
Cequr SimplicityBolus Insulin Pump, 200 Unit16$7,110
Levothyroxine Sodium434$6,157
TresibaInsulin Degludec11$5,790
Novolog FlexpenInsulin Aspart17$5,383

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Tresiba, Novolog$179$287,051185 claims
AmgenProlia$22$23,45114 claims
Cequr CorporationCequr Simplicity$195$7,11016 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 9,771 internal medicine providers in New York.

Other internal medicine in New York

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →